Pharmaceutical development for generic product powerpoint presentation slides
Try Before you Buy Download Free Sample Product
Impress Your Audience
100% Editable
Save Hours of Time
Our Pharmaceutical Development For Generic Product Powerpoint Presentation Slides are topically designed to provide an attractive backdrop to any subject. Use them to look like a presentation pro.
People who downloaded this PowerPoint presentation also viewed the following :
Content of this Powerpoint Presentation
Slide 1: This slide is titled “Pharmaceutical Development for Generic Product.” State your company name and get started.
Slide 2: This slide is titled “Agenda for Pharmaceutical Development for Generic Product.” It provides scientific information about the development of new drug products and the following manufacturing process.
Slide 3: This slide is titled “Table of Contents.” It covers Overview of Pharmaceutical Development, Information on Active Pharmaceutical Ingredients (API), Quality Target Product Profile, etc.
Slide 4: This slide is titled “Table of Contents.” It covers Introduction to Overview of Pharmaceutical Development.
Slide 5: This slide is titled “Overview of Pharmaceutical Development.” It addresses the pharmaceutical development of ABC tablets containing existing active pharmaceutical ingredients (APIs) of QPR origin.
Slide 6: This slide is titled “Table of Contents.” It covers General Information, Physicochemical Description, Composition, and Information on Active Pharmaceutical Ingredients (API).
Slide 7: This slide is titled “General Information on Active Pharmaceutical Ingredients.” It displays general information on active pharmaceutical ingredients. It covers ingredient name registration status and applications of each ingredient.
Slide 8: This slide is titled “Physicochemical Description of the Product.” It illustrates the physicochemical description of the tablet. It includes information such as batch number, expiry date, average weight, coating, and other physical statistics.
Slide 9: This slide is titled “Composition of the Product.” It provides the composition information about the tablet to be developed. It covers the ingredient name, its function, and its units.
Slide 10: This slide is titled “Table of Contents.” It shows Quality Target Product Profile, Critical Process Parameter, and Critical Quality Attributes.
Slide 11: This slide is titled “Quality Attribute.” It shows Target, Criticality, Justification, Dosage Form, Dosage Design, Dosage Strength, Dose Uniformity, etc.
Slide 12: This slide is titled “Critical Process Parameters of the Product.” The following table summarizes the critical process parameters of the product. It includes steps, control variables, and critical parameters to be checked in the manufacturing of tablets.
Slide 13: This slide is titled “Critical Quality Attributes of the Product.” It illustrates the critical quality attributes of the tablet. It covers various quality attributes, targets, criticality status, and justification.
Slide 14: This slide is titled “Table of Contents.” It shows Drug Substance, Excipients, Product Specifications, Components of the, and Drug product.
Slide 15: This slide is titled “Drug Substance Specification.” The following table shows specification information about drug substances. It includes attributes name, acceptance criteria, and analytical procedure for each attribute.
Slide 16: This slide is titled “Excipient in the Product.” It shows the excipient included in the tablet for commercialization. It covers excipient name, and quantity per tablet, and their function.
Slide 17: This slide is titled “Drug Product Specification.” It shows the drug product specification table. It includes attributes name, acceptance criteria, and analytical procedure for each attribute.
Slide 18: This slide is titled “Table of Contents.” It shows Formulation Development, Physical-chemical and Biological Properties, and Drug Products.
Slide 19: This slide is titled “Composition of Formulation Development Experiments.” The following table illustrates the composition of formulation development experiments. It includes ingredients details and their proportion in grams and percentage.
Slide 20: This slide is titled “Drug Product – Physical Properties.” It illustrates the physical properties of the drug substances. It includes physical description, solid-state form, melting point, density and flowability, and aqueous solubility.
Slide 21: This slide is titled “Drug Product – Chemical Properties.” It illustrates the chemical properties of the drug substance. It covers the pKa value of the product and chemical stability both in solid as well as solution state.
Slide 22: This slide is titled “Drug Product – Biological Properties.” It illustrates the biological properties of the drug substance. It includes partition coefficient, caco – 2 permeability, and biopharmaceutics classification.
Slide 23: This slide is titled “Table of Contents.” It includes Risk Assessment, Impacts on Drug Products, and Risk and Impact Assessment.
Slide 24: This slide is titled “Initial Risk Assessment of Critical Quality Attributes.” The following table is based on ICH Q9 quality risk management. It illustrates the risk assessment of critical quality attributes of the product.
Slide 25: This slide is titled “Initial Risk Assessment of Manufacturing Process Steps.” It shows the initial risk assessment of manufacturing process steps. It covers details of process step, output material, variables, risk assessment, and justification.
Slide 26: This slide displays Mixing Process Risk Assessment.” It shows a mixing process risk assessment. It includes unit operation, parameter, potential failure mode, the impact of change, a potential cause of failure, controls, and risk rating.
Slide 27: This slide displays the Potential Impact on Drug Products. The mentioned template shows the potential impact of the API attribute on the drug product. Attributes covered are particle size, salt form, moisture, crystallinity, purity, and solubility.
Slide 28: This slide is titled “Table of Contents.” It shows Manufacturing Process Step & Equipment Used, Process Steps & Associated Intermediates, Process Flow Diagram, and Manufacturing Process Development.
Slide 29: This slide is titled “Manufacturing Process Step and Equipment Used.” It shows manufacturing process steps and equipment used to make the steps achievable. Process steps included are roller compaction, blending, milling, lubrication, and compression.
Slide 30: This slide is titled “Process Steps and Associated Intermediates.” It shows critical process steps and their associated intermediates. It includes information about the unit operation, intermediate attributes, measurement methodology, and acceptance criteria.
Slide 31: This slide is titled “Manufacturing Process Flow Diagram.” It illustrates the manufacturing process flow diagram. It covers information such as process parameters, attributes of input materials, manufacturing process steps, and quality attributes of output material.
Slide 32: This slide is titled “Table of Contents.” It shows Description and Suitability, Control Strategy, and Container Closure System.
Slide 33: This slide is titled “Control Strategy Table.” The following table illustrates the control strategy for the commercial manufacture of tablets. It includes details such as factors, attributes for parameters, range studied, actual data, and proposed range and purpose of control.
Slide 34: This slide is titled “Control Strategy Table Cont.” The following table illustrates the control strategy for the commercial manufacture of tablets. It includes details such as factors, attributes for parameters, range studied, actual data, proposed range, and purpose of control.
Slide 35: This slide is titled “Container Closure System – Description and Suitability.” It shows the description and suitability information about the container closure system. It covers container suitability based on protection, safety, and compatibility.
Slide 36: This slide is titled “Table of Contents.” It shows the Product Development Roadmap and Product Lifecycle.
Slide 37: This slide is titled “Product Development Roadmap (1/2).” It illustrates the product development roadmap with quarterly division. The roadmap includes different product development tasks along with text holders.
Slide 38: This slide is titled “Product Development Roadmap (2/2).” It shows the product development roadmap. The roadmap includes different product development tasks along with description holders.
Slide 39: This slide is titled “Pharmaceutical Product Lifecycle.” The mentioned template displays the pharmaceutical product lifecycle. It covers strategies for all four stages namely introduction, growth, maturity, and decline.
Slide 40: This slide is titled “Pharmaceutical Development for Generic Product – Icons Slide.” You can use this icon slide for various use cases.
Slide 41: This slide is titled “Additional Slides.”
Slide 42: This slide is titled “Pharmaceutical Product Development Process.” It illustrates the development process of a pharmaceutical product. The process starts from the discovery stage and ends at the making commercial supplies stage.
Slide 43: This slide is titled “New Drug Approval Process.” This shows the Developmental Phase, Production & Pre- Commercial Phase, IND - Investigational New Drug, NDA - New Drug Application, and ANDA - Abbreviated New Drug Application.
Slide 44: This slide is titled “New Drug Product Development Matrix.” It shows Investigational New Drug (IND), Preapproval Inspection (PAI) to Support New Drug Application (NDA), and Manufacturing Process.
Slide 45: This slide is titled “Stacked Bar.” This slide shows a bar graph that compares 2 products’ sales over a timeline of financial years.
Slide 46: This slide is titled “Combo Chart.” This slide shows a bar graph that compares 2 products’ sales over a timeline of financial years.
Slide 47: This slide is titled “Post it Notes.” Add your ideas in this template.
Slide 48: This slide contains the information about the company aka the ‘About Us’ section. This includes the Valued Clients, the Target Audience, and Preferred by Many.
Slide 49: This slide shows a bar graph that compares 3 products’ sales over a timeline of financial years.
Slide 50: This slide is titled “Puzzle.” You can use this template to display your product or an idea implementation technique.
Slide 51: This slide presents a Magnifying Glass to give more details about the individual steps in a project.
Slide 52: This slide is titled “Goal.” Add your long-term and short-term goals.
Slide 53: This slide is a Timeline template to showcase the progress of the steps of a project with time.
Slide 54: This slide presents a Circular Diagram and the components that make up a project or concept.
Slide 55: This is a Thank You slide where details such as the address, contact number, and email address are added.
Pharmaceutical development for generic product powerpoint presentation slides with all 55 slides:
Use our Pharmaceutical Development For Generic Product Powerpoint Presentation Slides to effectively help you save your valuable time. They are readymade to fit into any presentation structure.
FAQs for Pharmaceutical development for generic product
So there's four phases to drug development, each one bigger than the last. First up is Phase I - just 20-100 people testing if it's safe. Then Phase II expands to a few hundred patients to see if the thing actually works. Phase III is where it gets expensive - thousands of people comparing your drug to what's already out there. Most people forget about Phase IV but that's the post-approval monitoring stuff. Each phase runs 1-3 years typically, though honestly timelines are all over the place depending on what you're treating. Pro tip: always pad your estimates because regulators will throw curveballs that mess everything up.
Yeah, so regulatory stuff will absolutely wreck your timeline and budget. We're talking years of extra delays, hundreds of millions more. First you've got all the preclinical work, then Phase I through III trials with the FDA breathing down your neck constantly. The paperwork is honestly ridiculous - some of these submissions are like phone books. Then after all that? You're still waiting 6-12 months just for them to decide. My biggest tip would be planning for regulatory from the start. Don't just tack it on later thinking it'll be fine.
Think of biomarkers as your crystal ball and backup plan. They help you find the right patients and predict who'll actually respond to your drug. Plus they catch safety red flags early - way better than discovering problems in Phase III (been there, nightmare fuel). During preclinical and Phase I, biomarkers show you're hitting your target and help nail down the right dose. You can prove biological activity even when clinical endpoints are still months away. Honestly, the trick is baking this into your plan from the start. Don't wait until you're scrambling to fix things later.
RWE is honestly a game-changer for drug development - it shows how your treatment actually works when real patients use it (not just in perfect trial conditions). You're pulling data from health records, insurance claims, patient registries, all that messy real-world stuff. It's incredible for catching safety issues you missed and figuring out which patients actually benefit. I've seen companies waste millions because they ignored this early on. Don't make RWE an afterthought - weave it into your strategy from day one or you'll regret it later.
So AI drug discovery is absolutely crushing it right now - predicting molecular stuff in days vs months. CRISPR's obviously huge for genetic diseases. What's really cool though is these digital organ twins that let you test compounds virtually before even touching animals. Saves tons of time. Advanced biomarkers are helping pick the right patients way earlier too, which honestly should've happened years ago. Your company should probably look into AI screening tools since everyone's using them now. The whole field's moving crazy fast - hard to keep up sometimes but exciting.
Honestly, getting patients involved early completely changes how you run trials. They'll spot stuff you'd never notice - like scheduling visits during dialysis or picking endpoints that don't actually matter to them. It's kinda embarrassing how much we miss! Their input helps you pick better primary endpoints and create protocols people can realistically follow. Plus they design way better patient-reported outcome measures than we do. The payoff is huge though - better enrollment, people stick around longer, and your data reflects what patients actually care about. Definitely get patient advocates in your protocol meetings from day one.
Honestly, the worst part is you're constantly flying blind. Innovation means there's barely any safety data to work with - you're trying to prove something works when you don't even know all the risks yet. Meanwhile, regulators want mountains of evidence (which, fair enough). Development timelines are breathing down your neck to move fast, but then you hit this brutal trade-off: sacrifice some efficacy for better safety, or risk it? I learned the hard way that you've got to build solid risk management from day one and keep talking to regulatory folks throughout. Otherwise you'll just hit walls later.
So the whole industry's shifting toward these tiny patient groups with specific biomarkers. Companies are dumping money into companion diagnostics to figure out who'll actually respond to their drugs - way smarter than the old spray-and-pray method. Manufacturing's getting modular too for smaller batches. The economics are weird though, not gonna lie. Plus there's all this partnering with tech companies for data stuff. Honestly, if you're looking at investments here, find companies building diagnostics right into their early development. That's where the money is.
So the big things you're dealing with are getting real informed consent and making sure the risks don't outweigh the benefits. Vulnerable populations are tricky - kids, pregnant women, people who might feel pressured financially. They can't always speak up for themselves, you know? The paperwork for consent is honestly such a pain, but people need to actually get what they're agreeing to. Your ethics board should definitely review everything first. Oh, and patient advocates for vulnerable groups can be super helpful. Just make sure the potential benefits are worth whatever risks you're putting people through.
Look, biotech has the cool science but they're basically broke. Pharma has deep pockets and knows how to navigate all the regulatory BS. So partnerships make total sense - biotech can stay nimble with research while pharma funds those crazy expensive Phase III trials. Risk gets split too, which is smart. Pharma taps into cutting-edge stuff without building everything from scratch. Biotech actually gets their discoveries to people instead of running out of money halfway through. When you're looking at these deals, just focus on what each side brings that the other doesn't have.
Pharma companies basically chase whatever health problems are trending globally. Aging populations everywhere? Boom - massive investments in Alzheimer's and cancer drugs. COVID totally flipped the script overnight and everyone rushed into vaccines and infectious disease research. Look at diabetes and obesity rates exploding - that's exactly why GLP-1 treatments are everywhere now. Companies follow the money though, which honestly sucks because they'll focus on rich countries' problems over stuff like tropical diseases. If you're mapping out pipeline strategy, just watch demographic shifts and whatever health crisis pops up next. That's where the industry will go.
Honestly, AI is a total game-changer for drug discovery. You can screen millions of compounds virtually without touching a lab - saves crazy amounts of time and money. Plus it predicts how molecules behave and spots promising targets way faster than old-school methods. The best part? It catches problematic compounds early, so you don't waste years on stuff that'll fail anyway. Clinical trial design gets way smarter too, and there's cool repurposing happening with existing drugs. Start with AI molecular modeling tools first - you'll see results pretty quick and it's not overwhelming to jump into.
Look, it's honestly pretty messed up how much your bank account determines what treatments you can get. Rich people jump on new drugs right away while everyone else waits for generics or just... doesn't get them. Insurance makes it worse with all their approval hoops and crazy deductibles. Plus if you live somewhere rural? Good luck finding the right pharmacy or specialist. Your zip code shouldn't decide if you live or die, but here we are. Companies need to bake in assistance programs from the start - tiered pricing, patient help, whatever it takes. Can't just slap that on later and call it good.
So many trials crash because teams skip the basics upfront. Start with better patient selection - biomarkers and genetic screening will find people who'll actually respond. Dosing strategy matters way more than people think, so don't rush your PK/PD studies. Pick endpoints that regulators and patients care about, not just what's convenient to measure. Adaptive designs are clutch since you can tweak protocols using interim data. Oh, and map out your regulatory path from the beginning. I've seen too many promising drugs die because someone treated FDA strategy like an afterthought.
Dude, COVID totally changed pharma development. Regulators started accepting real-world data and remote trials - stuff they should've been doing forever honestly. The whole thing proved you can shrink those crazy 10-15 year timelines to under a year when there's actual urgency. mRNA tech basically went mainstream overnight, and now companies are trying to use it for everything (not just vaccines). Oh, and if you're working on any projects - hybrid trial designs are your friend now. Digital endpoints too. Regulators actually listen to that stuff now instead of being stuck in 2005.
-
Use of different colors is good. It's simple and attractive.
-
Very well designed and informative templates.
-
Thanks for all your great templates they have saved me lots of time and accelerate my presentations. Great product, keep them up!
-
The content is very helpful from business point of view.
-
Excellent template with unique design.